BBI Solutions wins Dx Creative Award for Morffi™ launch

BBI Solutions is pleased to announce that it has triumphed at the DxMA’s 2017 Dx Creative Awards, winning the New IVD Product Launch (less than $100m) category for the market release of its Morffi™ signal enhancement technology. The awards ceremony (held in New Orleans, USA, on the 30th of April) was an opportunity to celebrate the latest innovations in the diagnostics field ahead of the DxMA Global Marketing Summit on the 1st of May, where BBI’s Dr Neil Polwart was also presenting the company’s Novarum Dx mobile assay reader.

Officially unveiled at Medica 2016, the patent-pending Morffi signal enhancement technology (offered exclusively through BBI’s development service) can enhance the sensitivity of lateral flow immunoassays (LFIs), opening up new opportunities and allowing LFIs to compete with traditional lab-based testing platforms. The Medica launch included a ‘first to see’ breakfast seminar and white paper presentation, supported by an integrated marketing campaign and eye-catching exhibition stand, and garnered interest from across the diagnostics sector. “We are thrilled at this recognition of the hard work and dedication of our team,” commented Liam Taylor, Managing Director of BBI Solutions. “In this highly regulated industry, a sceptical audience is always a major challenge, but we’ve worked hard to support this innovative technology with robust and reliable data, offering a simple, swap-in technology which we hope will transform the future of diagnostics.”


Morffi is available as part of BBI’s research and development services through a licensing model. If you’re interested in developing a lateral flow device or redeveloping an assay, visit www.bbisolutions.com.

BBI Solutions

BBI Solutions is a leading manufacturer of biological reagents and finished test platforms for the in-vitro diagnostics market. BBI is a global business with manufacturing sites spanning three continents.

Our range of raw materials includes human antigens, antibodies, serum and plasma products and clinical chemistry enzymes. We manufacture world renowned labels for lateral flow, ELISA assay and biosensors, including our gold nanoparticles and glucose oxidase.

BBI Solutions offer lateral flow development and manufacturing services with a core focus on gold conjugation and lateral flow test manufacture.

BBI Solutions is part of the BBI Group.



Rapid free light chain test granted registration in Brazil

Seralite®– FLC Serum granted registration by the Brazilian Health Regulatory Agency (ANVISA) Abing...

Read More >

EKF Diagnostics supporting reduction of anemia in developing regions in South America

Symposium highlights successful use of EKF’s Hemo Control hemoglobin analyzer in extreme environmen...

Read More >

Cytox in Collaboration with AKESOgen Extends Genetic Test for Assessing Alzheimer's Disease

8th May 2018: Oxford & Manchester, UK and Atlanta, GA. Cytox, a precision medicine testing company ...

Read More >

Press Release - RQM+ Appoints Life Science Executive Margaret Keegan as New CEO

RQM+, the world’s leading provider of regulatory, clinical and quality solutions to the MedTech ind...

Read More >

Evaluation studies confirm improved oncology patient pathways through HORIBA Medical’s new POC haematology analyser

Yumizen H500 full blood count analyser demonstrates exceptional correlation with larger laboratory-b...

Read More >

Radiometer sponsors World Sepsis Day 2017

In continuation of Radiometer’s commitment to the fight against sepsis – one of the world’s deadl...

Read More >